Apatinib for Inoperable Advanced Chondrosarcoma (AIAC)

Peking University

Status

Completed

Conditions

Toxicity, Drug

Efficacy

Treatments

Drug: Apatinib Mesylate

Study type

Interventional

Funder types

Other

Identifiers

NCT04260113

CSSG-06

Details and patient eligibility

About

Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.

Enrollment

40 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

1. histologically confirmed high-grade sarcoma;
1. initial treatment in the orthopedic oncology departments of the two affiliated hospitals of Peking University;
1. tumors not amenable to curative treatment or inclusion in clinical trials;
1. unresectable local advanced lesions or multiple metastatic lesions that could not be cured by local therapy;
1. measurable lesions according to Response Evaluation Criteria for Solid Tumors (RECIST1.1) ;
1. Eastern Cooperative Oncology Group performance status 0 or 1;
1. acceptable hematologic, hepatic, and renal function.

Exclusion criteria

had central nervous system metastasis;
had other kinds of malignant tumors at the same time; had cardiac insufficiency or arrhythmia;
had uncontrolled complications such as diabetes mellitus, coagulation disorders, urine protein ≥ ++ and so on;
had pleural or peritoneal effusion that needs to be handled by surgical treatment;
combined with other infections or wounds;
pregnant or breastfeeding.